Altering Calcium Sensitivity in Heart Failure: A Crossroads of Disease Etiology and Therapeutic Innovation

Nancy S Saad1,2,3, Mohammed A Mashali1,2,4, Steven J Repas5

  • 1Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.

Insights

Altering calcium sensitivity in heart failure (HF) offers new treatment avenues. Precise modulation of myofilament calcium sensitivity could improve cardiac function and prevent arrhythmias, revolutionizing HF care.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Cardiology
  • Biophysics

Background:

  • Heart failure (HF) treatments primarily manage symptoms, not disease progression.
  • Calcium (Ca2+) regulation is a promising target for novel HF therapies.
  • Altered Ca2+ sensitivity impacts cardiac contractility in HFpEF and HFrEF.

Purpose of the Study:

  • To review the role of altered Ca2+ sensitivity in HF.
  • To explore the implications of Ca2+ binding and dissociation kinetics (kon, koff) in HF.
  • To discuss therapeutic strategies targeting myofilament Ca2+ sensitivity.

Main Methods:

  • Literature review focusing on Ca2+ regulation in HF.
  • Analysis of Ca2+ sensitivity's impact on systolic and diastolic function.
  • Examination of rate constants (kon, koff) in cardiac muscle dynamics.

Main Results:

  • Altered Ca2+ sensitivity is central to HF pathophysiology.
  • Increased Ca2+ sensitivity enhances systole but risks diastolic dysfunction and arrhythmias.
  • Modulating Ca2+ sensitivity offers potential anti-arrhythmic benefits.

Conclusions:

  • Precision targeting of myofilament Ca2+ sensitivity is crucial for HF treatment.
  • Understanding Ca2+ kinetics is key to developing effective therapies.
  • Further research is needed on Ca2+ regulation and HF clinical manifestations.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
394
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
519
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K